Deribit's options products have been integrated with the institutional trading platform CoinRoutes. Institutional traders can now trade Deribit's spot, futures, and options through CoinRoutes. The first supported products include Bitcoin (BTC) and Ethereum (ETH) reverse options, as well as linear options for Bitcoin, Ethereum, Solana (SOL), and Ripple (XRP). CoinRoutes users can utilize real-time buy and sell quotes, the Greeks (option sensitivity indicators), and portfolio risk and profit and loss (PnL) monitoring features. This integration aims to expand institutional trading infrastructure, with CoinRoutes providing algorithmic trading and order routing services. CoinRoutes announced plans to enhance its options-specific order ticket and sweep functionality through its integration with Deribit, which began in February of this year. Deribit is a cryptocurrency exchange specialized in options and futures, currently supporting Bitcoin and Ethereum reverse options, as well as USD Coin (USDC) settlement options for various altcoins. In institutional trading, order routing involves comparing quotes from multiple exchanges to send orders, increasing the need for integrated portals and APIs. This integration signifies the consolidation of institutional trading channels, allowing for the management of Deribit products without a separate interface.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.













